140 related articles for article (PubMed ID: 23084530)
1. Targeting angiogenesis as a promising modality for the treatment of prostate cancer.
Lin J; Kelly WK
Urol Clin North Am; 2012 Nov; 39(4):547-60. PubMed ID: 23084530
[TBL] [Abstract][Full Text] [Related]
2. The role of angiogenesis inhibitors in prostate cancer.
Aragon-Ching JB; Dahut WL
Cancer J; 2008; 14(1):20-5. PubMed ID: 18303479
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenesis in prostate cancer: knocked down but not out.
Bilusic M; Wong YN
Asian J Androl; 2014; 16(3):372-7. PubMed ID: 24759579
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab treatment of prostate cancer.
Small AC; Oh WK
Expert Opin Biol Ther; 2012 Sep; 12(9):1241-9. PubMed ID: 22775507
[TBL] [Abstract][Full Text] [Related]
5. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic therapy: concept to clinic.
Young RJ; Reed MW
Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Merino M; Pinto A; González R; Espinosa E
Eur J Cancer; 2011 Aug; 47(12):1846-51. PubMed ID: 21600762
[TBL] [Abstract][Full Text] [Related]
8. [VEGF in neoplastic angiogenesis].
Chekhonin VP; Shein SA; Korchagina AA; Gurina OI
Vestn Ross Akad Med Nauk; 2012; (2):23-33. PubMed ID: 22642175
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with antiangiogenic therapy in leukemia.
Wellbrock J; Fiedler W
Curr Cancer Drug Targets; 2011 Nov; 11(9):1053-68. PubMed ID: 21999626
[TBL] [Abstract][Full Text] [Related]
10. Design of clinical trials of radiation combined with antiangiogenic therapy.
Senan S; Smit EF
Oncologist; 2007 Apr; 12(4):465-77. PubMed ID: 17470689
[TBL] [Abstract][Full Text] [Related]
11. VEGF inhibitors and prostate cancer therapy.
Aragon-Ching JB; Dahut WL
Curr Mol Pharmacol; 2009 Jun; 2(2):161-8. PubMed ID: 19617926
[TBL] [Abstract][Full Text] [Related]
12. Novel therapies for metastatic castrate-resistant prostate cancer.
Dayyani F; Gallick GE; Logothetis CJ; Corn PG
J Natl Cancer Inst; 2011 Nov; 103(22):1665-75. PubMed ID: 21917607
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis as targeted breast cancer therapy.
Hayes DF; Miller K; Sledge G
Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641
[TBL] [Abstract][Full Text] [Related]
14. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
[TBL] [Abstract][Full Text] [Related]
15. Novel agents for the treatment of advanced kidney cancer.
Cooney MM; Remick SC; Vogelzang NJ
Clin Adv Hematol Oncol; 2004 Oct; 2(10):664-70. PubMed ID: 16163253
[TBL] [Abstract][Full Text] [Related]
16. [Novelties in the treatment for advanced renal-cell cancer].
Maráz A
Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
[TBL] [Abstract][Full Text] [Related]
17. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.
Schweizer MT; Carducci MA
Cancer J; 2013; 19(1):99-106. PubMed ID: 23337763
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular toxicity of new agents.
Maitland ML
Clin Adv Hematol Oncol; 2008 Sep; 6(9):657-9. PubMed ID: 18827788
[No Abstract] [Full Text] [Related]
19. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Rini BI
Cancer; 2009 May; 115(10 Suppl):2306-12. PubMed ID: 19402073
[TBL] [Abstract][Full Text] [Related]
20. [The role of angiogenesis in renal carcinoma].
Bussolati B; Satolli MA; Camussi G
G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]